Gregory Pogue, Ph.D.
Vice President, Regulatory

Gregory Pogue serves as Vice President of Business Development for Emergent Technologies, Inc., and currently serves on the management team for ETI portfolio company Caisson Biotech as Vice President, Regulatory.

As Vice President of Business Development at Emergent Technologies, Dr. Pogue is responsible for evaluating the commercial potential of new technologies, determining both technical and market trajectories, and building partnerships to effectively commercialize products. Dr. Pogue brings over twenty years of experience in biologic development, spanning research management, biologic regulation, and intellectual property development and licensing. Dr. Pogue most recently served as Licensing Associate for the University of Texas at Austin where he negotiated licenses with companies ranging from newly formed startups to Fortune 500 enterprises.

Before coming to Texas, Dr. Pogue served as Vice President of Research and Development at Large Scale Biology Corporation (LSBC), where he managed a broad development program involving product development and preclinical and clinical testing of numerous lead compounds, including two receiving Orphan Drug Designation from the US FDA and 16 successfully completing early clinical trials. He also developed licensing and R&D contracts with corporate, academic, and government entities and supervised collaborative research relationships. Before joining LSBC, Dr. Pogue worked in the U.S. FDA's Center for Biologics Research and Evaluation as a scientist with Investigational New Drug and Biological Licensing Application review responsibilities. He holds a B.S. from Midwestern State University and a Ph.D. from Texas A&M University. Pogue has published numerous original scientific articles and reviews, is an inventor on multiple U.S. patents, and is a frequent invited speaker at national and international scientific meetings.